Evolent Health, Inc. reported financial results for the quarter ended June 30, 2026, showing revenue of $652.5 million compared to $444.3 million in the prior year period. The company posted a net loss attributable to common shareholders of $28.4 million, narrowing from $51.1 million previously, while Adjusted EBITDA declined to $28.1 million from $37.5 million. Evolent raised its full-year 2026 revenue guidance to $2.6–$2.7 billion and tightened the Adjusted EBITDA range to $120–$135 million. Management highlighted a new Oncology Performance Suite partnership covering approximately 1.5 million lives, expected to launch by December 2026 with $300 million in annualized revenue potential. The company also provided a 2027 outlook projecting over 25% revenue growth and an Adjusted EBITDA midpoint of at least $150 million. Evolent Health operates in the healthcare industry, specializing in complex specialty care management solutions for payers and providers.